| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:18 | Lexaria completes dosing in semaglutide drug delivery study | 5 | Investing.com | ||
| 15:02 | Lexaria Bioscience Corp.: Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled | 271 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / November 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that final dosing has... ► Artikel lesen | |
| 04.11. | Lexaria enters drug delivery tech agreement with pharma firm | 9 | Investing.com | ||
| 04.11. | Lexaria Bioscience Corp.: Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH | 267 | ACCESS Newswire | Third pharmaceutical company relationship entered KELOWNA, BC / ACCESS Newswire / November 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery... ► Artikel lesen | |
| 28.10. | Lexaria Bioscience receives four patents for drug delivery technology | 3 | Investing.com | ||
| LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 28.10. | Lexaria Bioscience Corp.: Lexaria Celebrates its 70th Patent Award | 416 | ACCESS Newswire | New patents awarded in the US, Canada, and EuropeIP protection for treatments for Epilepsy, Diabetes, and Hypertension KELOWNA, BC / ACCESS Newswire / October 28, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)... ► Artikel lesen | |
| 21.10. | Lexaria completes enrollment in semaglutide drug delivery study | 2 | Investing.com | ||
| 21.10. | Lexaria Bioscience Corp.: Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule | 419 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has... ► Artikel lesen | |
| 15.10. | Lexaria Bioscience Corp.: Lexaria Announces Results from Animal Study GLP-1-A26-1 | 459 | ACCESS Newswire | Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria")... ► Artikel lesen | |
| 06.10. | Lexaria Bioscience Corp.: GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications | 576 | ACCESS Newswire | Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS... ► Artikel lesen | |
| 17.09. | Lexaria Bioscience Corp.: Lexaria Updates Financial Position | 477 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria... ► Artikel lesen | |
| 09.09. | Lexaria Bioscience Corp.: Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds | 591 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced... ► Artikel lesen | |
| 09.09. | Lexaria Bioscience Corp. - 8-K, Current Report | 4 | SEC Filings | ||
| 08.09. | Lexaria Bioscience announces $5.9M warrant exercise | 6 | Seeking Alpha | ||
| 08.09. | Lexaria Bioscience Corp.: Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds | 372 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced... ► Artikel lesen | |
| 04.09. | Lexaria Bioscience Corp.: Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference | 471 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate... ► Artikel lesen | |
| 01.09. | Lexaria Bioscience advances 12% on Australian tax rebate | 3 | Seeking Alpha | ||
| 01.09. | Lexaria receives $2.6M R&D tax rebate from Australian Tax Office; shares up over 14% | 2 | Seeking Alpha | ||
| 01.09. | Lexaria receives $2.6 million Australian R&D tax rebate | 5 | Investing.com | ||
| 01.09. | Lexaria Bioscience Corp.: Lexaria Receives USD$2.6 Million Tax Rebate Payment | 433 | ACCESS Newswire | Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company")... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 51,78 | -3,09 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius schließt Verkauf von 13,4 Millionen Aktien der Fresenius Medical Care zu 39,00 Euro je Aktie ab und erzielt rund 524 Millionen Euro | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
Fresenius schließt Verkauf von 13,4 Millionen Aktien der Fresenius Medical Care zu 39,00... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,260 | 0,00 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 27 auf 26 Euro gekappt und die Aktien von "Equal Weight" auf "Underweight" abgestuft. Dem... ► Artikel lesen | |
| INTUITIVE SURGICAL | 370,00 | -3,51 % | BMO bekräftigt Einstufung für Intuitive Surgical angesichts des Wachstumspotenzials bei ambulanten OP-Zentren | ||
| UNITEDHEALTH | 302,80 | -5,02 % | UnitedHealth-Aktie -15%: Washington zieht die Daumenschrauben an - trotzdem kaufen? | Es ist bislang eine rabenschwarze Woche für die UnitedHealth-Aktie. Am Dienstag und am Mittwoch brach der Kurs der größten privaten US-Krankenversicherung in Summe um -15% ein. Was steckt hinter dem... ► Artikel lesen | |
| DRAEGERWERK | 115,80 | -2,69 % | EQS-News: Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener Aktien - Abschlussmeldung | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Sonstiges
Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener... ► Artikel lesen | |
| MEDTRONIC | 91,46 | -0,33 % | Medtronic: What Happens When Healthcare Technology Starts With People | From living rooms to operating rooms, human-centered design is informing the future of tech?Key takeawaysHuman-centered design at Medtronic uses patient, caregiver, and clinician insights to make medical... ► Artikel lesen | |
| GERRESHEIMER | 33,000 | -0,60 % | Gerresheimer: Warum jetzt alles am Schlussquartal hängt | ||
| THERMO FISHER | 625,80 | -0,89 % | 65% der untersuchten FDA-Rückschläge betrafen Produktionsstätten: Die unsichtbare Hürde für Lonza, Thermo Fisher und NeuroThera | ||
| TELADOC HEALTH | 7,106 | -3,29 % | Truist raises Teladoc stock price target to $9 on EBITDA outlook | ||
| HIMS & HERS HEALTH | 14,790 | -4,83 % | Hims & Hers Health, Inc: Hers launches free Metabolic Deep Dive to help show UK women what's really holding back their weight loss | Hers launches free Metabolic Deep Dive to help show UK women what's really holding back their weight loss
New YouGov research finds 61% of UK women are trying to lose weight, yet many are working... ► Artikel lesen | |
| M1 AESTHETICS | 13,300 | 0,00 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,059 | -9,76 % | Sernova Biotherapeutics: 11,2 Millionen Dollar für die Fusion - und doch rutscht die Aktie | ||
| M1 KLINIKEN | 17,560 | -7,97 % | EQS-Adhoc: M1 Kliniken AG: M1 Kliniken plant für 2027 den Wechsel in den Prime Standard und hebt das EBIT-Margenziel im Beauty-Segment auf mindestens 25 % an | EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e): Strategische Unternehmensentscheidung/Prognose / Sonstige
M1 Kliniken AG plant für 2027 den Wechsel in den Prime Standard und... ► Artikel lesen | |
| ALCON | 68,38 | +1,45 % | 1,8 Milliarden Menschen mit Alterssichtigkeit: Warum Alcon und EssilorLuxottica neue Sehlösungen entwickeln | ||
| DEXCOM | 73,40 | -2,39 % | DexCom, Inc.: Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone | Opening ceremony attended by Minister for Public Expenditure, Infrastructure, Public Service Reform and Digitalisation, Jack Chambers, TD; Minister for Enterprise, Tourism and Employment, Peter... ► Artikel lesen |